The largest database of trusted experimental protocols

Pha m

Manufactured by Merck Group
Sourced in United States

PHA-M is a laboratory centrifuge designed for routine separation and sedimentation of various samples in a research or diagnostic setting. It features adjustable speed and time controls to accommodate different sample types and separation requirements. The PHA-M is a compact, reliable, and easy-to-use centrifuge suitable for a range of laboratory applications.

Automatically generated - may contain errors

20 protocols using pha m

1

Cytokine Induction by Fiber NANPs in PBMCs

Check if the same lab product or an alternative is used in the 5 most similar protocols
To stimulate PBMCs with fiber NANPs for the
assessment of cytokine
induction, cells were brought up to 1.25 × 106 cells/mL
and seeded in 96-well U-bottomed plates with 200 μL per well.
RNA/DNA fibers at 1 μM stock solution were complexed to Lipofectamine
2000 (L2K) at a 5:1 v/v ratio. After a 30 min incubation at room temperature,
OptiMEM was added, bringing the final concentration of fibers to 50
nM. Afterward, 40 μL of the prepared controls and NANPs were
added to PBMC for a final stimulation concentration of 10 nM. As the
positive controls, LPS (final 20 ng/mL, Invitrogen), ODN2216 (final
5 μg/mL), and PHA-M (final 10 μg/mL, Sigma) were added
to PBMCs. As a negative control, blank media was added to PBMCs. All
treatments were added to wells in technical duplicates for each donor.
After 20 h of incubation at 37 °C, the plate was spun down at
700g for 10 min. 170 μL of supernatant was
collected from each well and transferred into a new 96-well plate
for analysis of cytokines by multiplexed ELISA (Q-Plex Mouse Cytokine
– Inflammation (14-plex) and Q-Plex Human Cytokine –
HS Screen (15-plex) from Quansys Biosciences) according to the manufacturer’s
instructions. Supernatants from the three positive controls were pooled
1:1:1. Plates were imaged on a Quansys Biosciences Q-View Imager Pro.63 (link)
+ Open protocol
+ Expand
2

T Cell Proliferation Assay with BMDCs

Check if the same lab product or an alternative is used in the 5 most similar protocols
Splenic CD4+ T cells were isolated using magnetic‐activated cell sorting (MACS; Miltenyi Biotec, Bergisch Gladbach, Germany) according to the manufacturer's protocol. Briefly, positive selection of CD4+ T cells from 8‐week‐old C57BL/6 mouse spleens was performed according to the manufacturer's protocol using CD4 Microbeads (Miltenyi Biotec). CD4+ T cells (2 × 105 cells/well), stimulated with phytohemagglutinin‐M (PHA‐M) (5 μg/ml, Sigma‐Aldrich, St. Louis, MO, USA), were co‐cultured with allogeneic BMDCs (2 × 104 cells/well) in complete medium. For T cell proliferation assay, BMDCs were stimulated with Necrotic‐S or transfected with miRNA precursors or inhibitors. T cell proliferation was determined by thymidine incorporation on days 2, 5 and 7. To determine cell proliferation, cells were pulsed with [3H] thymidine during the last 18 hrs of culture and incorporated radioactivity was quantified using a liquid scintillation counter (Beckman, Fullerton, CA, USA).
+ Open protocol
+ Expand
3

Modulation of Cellular Pathways using Pharmacological Agents

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cells were treated with the following compounds: FOXO inhibitor / AS1842856 (344355, Calbiochem); TNFα (300–01A, PeproTech); Raltegravir (CDS023737, Sigma-Aldrich); Prostratin (P4462, LC Laboratories); PHA-M (10576015, Sigma-Aldrich); IL-2 (I2644, Sigma-Aldrich); αCD3 (40–0038, Tonbo Biosciences); αCD28 (70–0289, Tonbo Biosciences); PMA (P8139, Sigma-Aldrich); Ionomycin (I0634, Sigma-Aldrich); PERK inhibitor II / GSK2656157 (504651, Sigma-Aldrich); PERK inhibitor / AMG PERK 44 (5517, Tocris); GCN2 inhibitor / A-92 (2720, Axon Medchem); Imidazolo-oxindole PKR inhibitor C16 (I9785, Sigma-Aldrich); IRE1α inhibitor / MKC8866 (HY-104040, MedChem Express); Cyclosporin A (C3662, Sigma-Aldrich); Thapsigargin (T9033, Sigma-Aldrich); Tunicamycin (T7765, Sigma-Aldrich); Brefeldin A 1,000X Solution (00–4506-51, ThermoFisher Scientific); Fenretinide (17688, Cayman Chemicals).
+ Open protocol
+ Expand
4

Modulation of Cellular Pathways using Pharmacological Agents

Check if the same lab product or an alternative is used in the 5 most similar protocols
Cells were treated with the following compounds: FOXO inhibitor / AS1842856 (344355, Calbiochem); TNFα (300–01A, PeproTech); Raltegravir (CDS023737, Sigma-Aldrich); Prostratin (P4462, LC Laboratories); PHA-M (10576015, Sigma-Aldrich); IL-2 (I2644, Sigma-Aldrich); αCD3 (40–0038, Tonbo Biosciences); αCD28 (70–0289, Tonbo Biosciences); PMA (P8139, Sigma-Aldrich); Ionomycin (I0634, Sigma-Aldrich); PERK inhibitor II / GSK2656157 (504651, Sigma-Aldrich); PERK inhibitor / AMG PERK 44 (5517, Tocris); GCN2 inhibitor / A-92 (2720, Axon Medchem); Imidazolo-oxindole PKR inhibitor C16 (I9785, Sigma-Aldrich); IRE1α inhibitor / MKC8866 (HY-104040, MedChem Express); Cyclosporin A (C3662, Sigma-Aldrich); Thapsigargin (T9033, Sigma-Aldrich); Tunicamycin (T7765, Sigma-Aldrich); Brefeldin A 1,000X Solution (00–4506-51, ThermoFisher Scientific); Fenretinide (17688, Cayman Chemicals).
+ Open protocol
+ Expand
5

Confocal Imaging of HIV in HeLa, MDM, and CD4+ T Cells

Check if the same lab product or an alternative is used in the 5 most similar protocols
For confocal imaging (ViewHIV and immunostaining), HeLa-T4+ cells overexpressing CD4 (NIH AIDS Reagent Repository #154) were plated on glass coverslips in 24-well plates 24h prior to infection or transfection. HeLa cells were grown in DMEM with 10% FBS and L-glutamine (Invitrogen 25030081). MDMs and CD4+ T cells were from anonymous human donors per an existing IRB protocol. Each MDM and CD4+ T cell experiment was performed using a unique donor’s cells. MDMs and CD4+ T cells were purified using published methods (Zhu et al., 2014 (link)). Base media for culturing the MDMs and CD4+ T cells was RPMI-1640 (Sigma R0883) with 10% FBS (Invitrogen 26140079) supplemented with Non-Essential Amino Acids (Invitrogen 11140-076), and Sodium Pyruvate (Invitrogen 11360-070). MDMs were differentiated in GMCSF (Roche) after plating on glass coverslips in 24-well plates. CD4+ T cells were cultured with IL-2 (50 units/ml., Roche) and PHA-M (5 micrograms/ml., Sigma L8902). U20S cells (ATCC) were stably transduced with the Tet-On 3G activator (Clontech). The U20S-T3G cells were then stably transduced with a Tet-inducible full length MxB cDNA.
+ Open protocol
+ Expand
6

Isolation and Expansion of PHA-activated PBMCs

Check if the same lab product or an alternative is used in the 5 most similar protocols
PBMC from patients and haploidentical donors were isolated by Lympholyte-H (Cedarlane Laboratories) density-gradient centrifugation. To obtain PHA-blasts, PBMC were stimulated with the mitogen phytohemagglutinin-M (PHA-M, 1μg/mL; Sigma-Aldrich) and cultured in RPMI 1640 medium (Lonza) supplemented with 10% FBS (Euroclone), 2 mM L-glutamine (Lonza), 100 U/mL penicillin-streptomycin (Lonza) and Interleukin (IL)-2 (300IU/ml) (Proleukin, Clinigen Healthcare Ltd.).
+ Open protocol
+ Expand
7

Lymphocyte Proliferation Assay using AgNPs

Check if the same lab product or an alternative is used in the 5 most similar protocols
Lymphocyte proliferation was measured using CellTiter 96® AQueous One Solution Reagent (Promega, USA). Peripheral blood mononuclear cells (PBMCs) were collected from fresh human whole blood by Ficoll solution (GE Healthcare, USA). After washing cells by 1 × DPBS, 1 × 105 PBMCs in 100 μL RPMI-1640 medium were seeded in each well of 96-well round bottom plates. Then AgNPs, RPMI-1640 as negative control, 10 μg/mL phytohemagglutinin (PHA-M, Sigma-Aldrich, USA) as positive control, blank control were added into the plate, followed by incubating at 37 °C for three days. 40 μL MTS reagent was added into each well. After 4 h incubation at 37 °C, the absorbance (OD) at 490 nm as well as 650 nm as a reference wavelength was detected via an EnSpire® multimode plate reader (PerkinElmer, USA). The percentage of cell proliferation was calculated as the following formula: % cell proliferation = (Mean ODsample - Mean ODnegative control)/Mean ODnegative control × 100%.
+ Open protocol
+ Expand
8

Generating Polyclonal NK Cells from AML Patients

Check if the same lab product or an alternative is used in the 5 most similar protocols
Eighty-four AML patients aged 18–79 years in first CR who were not eligible for allogeneic stem cell transplantation were enrolled in a phase IV clinical trial (Re:Mission). Three patients withdrew consent; the other patients received 10 consecutive 3-week courses of HDC (0.5 mg, subcutaneously twice daily) and low-dose IL-2 (16 400 IU/kg, subcutaneously twice daily) over a period of 18 months. Two patients received allogeneic transplantation after relapse, but died within the follow-up period and were included as events in the OS analysis. Results for primary end points and patient characteristics can be found in references 14 15 34 35 (link). Patient samples were collected before and after the first treatment cycle. Healthy donor peripheral blood mononuclear cells (PBMCs) were isolated using density gradient centrifugation with Lymphoprep (Stemcell Technologies). NK cells were generated by negative selection using MACS NK isolation kit (Miltenyi Biotec). To generate polyclonally activated NK cells, NK cells were cultured with irradiated 221G and allogeneic PBMCs in complete medium supplemented with 600 IU/mL IL-2 (Chiron) and 5 µg/mL phytohemagglutinin (PHA-M, Sigma). After 5 days, the medium was gradually replaced with the same medium without PHA-M.
+ Open protocol
+ Expand
9

Activation of Latent HIV-1 in Cell Lines

Check if the same lab product or an alternative is used in the 5 most similar protocols
ACH-2, A3.01 and J-Lat cell lines were obtained through the NIH AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, NIH (ACH-2 cell line from Dr. Thomas Folks [26 (link), 27 (link)]; J-Lat Full Length Clones from Dr. Eric Verdin [28 (link), 29 (link)]) and were maintained in RPMI containing 10 % FBS, 1 % l-glutamine and 1 % penicillin–streptomycin (GIBCO). Multiple J-Lat cell lines derived from the same parent cell line, Jurkat T cell line, were included in our study. These cell lines contain either a full length GFP reporter virus (HIV-1 ΔNΔE-GFP) (3 cell clones—FL8.4, FL9.2 and FL10.6) or LTR–Tat-IRES-GFP (5 cell clones—TG82, TGA1, TGA2, TGA7 and TGH2). SAHA (suberoylanilide hydroxamic acid), prostratin, TNF-α and PHA-M (Phytohemagglutanin-M) were obtained from Sigma-Aldrich and R&D Systems. IΚK2 inhibitor V and SB203580 were obtained from CalBiochem. FK506 (Tacrolimus), Cyclosporin A and SB600125 were purchased from Abcam Biochemicals. Rottlerin, U0126 and WP 1066 were obtained from Sigma-Aldrich, Cell Signaling Technology and Enzo Life Sciences, respectively. In time kinetic experiments, the cells were treated with a compound and cells were collected at multiple time points from the single pool to reduce variability between time points within an experiment (paired design, repeated measures).
+ Open protocol
+ Expand
10

Isolation and Activation of Human Lymphocytes

Check if the same lab product or an alternative is used in the 5 most similar protocols
Human lymphocytes were kindly gifted by Dr. Irina I. Marakhova (Institute of Cytology, St. Petersburg, Russia). Cells were isolated from fresh venous blood of healthy donors according to the procedure described in [42] (link) and suspended in RPMI-1640 medium supplemented with 2 mM glutamine and 5% heat-inactivated human serum (AB IV Rh+). To activate quiescent lymphocytes for proliferation, at the next day after isolation, the cell suspension (>85% CD3+ cells) was adjusted to the concentration of 1.5•106 cells/ml, was added with phytohemagglutinin (PHA-M, Sigma, USA) at the final concentration of 10 μg/ml and incubated at 37 °C in a humidified chamber with 5% CO2 for 48 h.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!